Tyra Biosciences prices $400 million stock offering
The company priced 9,079,000 shares plus pre-funded warrants at $22.03, expecting to close September 15, 2026 and net about $373.9 million for its FGFR3 programs.
SEC filing (2)
Latest
4 stories
Monday, September 14
Tuesday, September 1
Polaryx Therapeutics names Will Charlton chief medical officer ahead of Phase 2 trial
Charlton, a pediatric endocrinologist with rare disease drug development experience, joined effective September 1, 2026 as Polaryx prepares to start its SOTERIA trial in the fourth quarter.
SEC filing
Tuesday, August 4
Tyra Biosciences expands at-the-market stock program to $250 million
Tyra amended its sales agreement with TD Cowen on August 4, 2026, after fully using a prior $150 million facility, raising the ceiling on shares it can sell through the program.
SEC filing
Tyra reports Q2 2026 results, sets September readout for dabogratinib bladder cancer trial
Tyra says initial SURF302 data are expected in September 2026, while a BEACH301 achondroplasia readout slips to end of Q1 2027 as a fifth dose level is added.
SEC filing